Recently, Grand Pharma (China) Co., Ltd. (hereinafter “Grand Pharma”) has been shortlisted for the Third “New Fortune Best IR of Hong Kong Listed Company” award. This award underscores the industry’s recognition of the development and accumulated achievements of the company over the years.

Many professionals specializing in the analysis of Hong Kong stocks, such as analysts from securities companies, QDII fund managers, and investment managers, have been invited to vote for the selection of this year’s New Fortune Best IR of Hong Kong Listed Company awards. Eventually, 40 companies, including Grand Pharma, were chosen from out of over 400 Hong Kong-listed companies with qualified IR teams.

In recent years, Grand Pharma’s business development strategy has been centered upon independent R&D and extensive acquisition. The company’s main business operations now cover three categories, namely, cardiovascular and cerebrovascular diseases, cancer, and respiratory system diseases. Its products cover the fields of pharmaceutical preparations and medical equipment, biotechnology and health products, and premium active pharmaceutical ingredients.

According to the 2019 earnings report (unaudited) released by Grand Pharma on March 27, compared to the same period in 2018, the company’s revenue grew by 10.6% to HKD 6.59 billion, while net profits grew by 61.4% to HKD 1.15 billion.

Grand Pharma has secured a strong first-mover advantage in terms of the number of product varieties, the reserve of core bestselling varieties, collaborative capacity in R&D, commercialization capabilities, and more.